Background: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial
pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first …

Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic
interstitial lung disease with an estimated median survival of only 2-3 years from initial …

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with
an estimated median survival of only 3 years after diagnosis. Pirfenidone is the only …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease, with a median survival time of 2–
5 years. The search for effective treatment has involved numerous clinical trials of …

Background Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five
randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and lethal fibrosing
interstitial pneumonia. The median survival from the onset of the symptoms is 2.8–4.2 years …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease without proven effective
therapy. A multicentre, double-blind, placebo-controlled, randomised phase III clinical trial …

Summary Background In this retrospective Italian study, which involved all major national
interstitial lung diseases centers, we evaluated the effect of pirfenidone on disease …

OBJECTIVE To evaluate the published clinical literature on the role of pirfenidone for the
treatment of idiopathic pulmonary fibrosis (IPF). DATA SOURCES A systematic literature …